Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BIAF

BioAffinity Technologies Inc

Apr 17 • 04:00PM ET

2.86

+0.10 3.62 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: CDXS AVDX BNGO CRSP EDIT NTLA SGMO BLUE GILD VRTX

| Held by: VXF DFAS DFMC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-15.41	Insider Own	3.38%	Shs Outstand	4.50M	Perf Week	-14.63%
Market Cap	12.87M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.35M	Perf Month	17.70%
Enterprise Value	7.58M	PEG	-	EPS next Q	-	Inst Own	5.31%	Short Float	12.46%	Perf Quarter	101.41%
Income	-14.91M	P/S	2.09	EPS this Y	-	Inst Trans	-8.89%	Short Ratio	0.06	Perf Half Y	5.54%
Sales	6.16M	P/B	1.77	EPS next Y	-	ROA	-170.65%	Short Interest	0.54M	Perf YTD	142.37%
Book/sh	1.62	P/C	2.00	EPS next 5Y	-	ROE	-301.83%	52W High	17.44 -83.60%	Perf Year	-81.49%
Cash/sh	1.43	P/FCF	-	EPS past 3/5Y	45.79% 21.77%	ROIC	-185.11%	52W Low	0.69 312.70%	Perf 3Y	-94.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	986.60% -	Gross Margin	23.21%	Volatility	10.34% 23.22%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1.23	EPS Y/Y TTM	31.46%	Oper. Margin	-171.58%	ATR (14)	0.55	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.58	Sales Y/Y TTM	-34.18%	Profit Margin	-241.96%	RSI (14)	47.72	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.60	EPS Q/Q	88.67%	SMA20	-21.43%	Beta	-1.05	Target Price	180.00
Payout	-	Debt/Eq	0.16	Sales Q/Q	-27.85%	SMA50	28.96%	Rel Volume	0.03	Prev Close	2.76
Employees	57	LT Debt/Eq	0.11	Earnings	Mar 13 BMO	SMA200	-25.56%	Avg Volume	8.84M	Price	2.86
IPO	Sep 01, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	266,189	Change	3.62%

Apr-14-26 08:00AM	New Case Study: bioAffinity Technologies CyPath Lung Diagnostic Supports Physicians Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy (Business Wire) -11.64%
Apr-07-26 08:00AM	bioAffinity Technologies CyPath Lung to Be Featured at Cleveland Clinic Annual Advances in Early Lung Cancer Detection Symposium April 16 (Business Wire)
Apr-01-26 08:00AM	bioAffinity Technologies CyPath Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026 (Business Wire)
Mar-25-26 08:00AM	bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath Lung into Pulmonary Practice (Business Wire)
Mar-17-26 07:45AM	New Case Study: bioAffinity Technologies CyPath Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures (Business Wire) +43.46%
08:00AM	Loading…
Mar-13-26 08:00AM	bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath Lung (Business Wire) +98.13%
Mar-10-26 07:47AM	bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath Lung Cancer Diagnostic (Business Wire) +12.26%
Mar-05-26 11:51AM	BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now? (Zacks)
Mar-03-26 08:30AM	bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients (Business Wire) -10.31%
Feb-25-26 08:30AM	bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath Lung Noninvasive Early Detection Lung Cancer Test (Business Wire)
Feb-19-26 11:00AM	New Case Study Highlights Ability of bioAffinity Technologies CyPath Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer (Business Wire)
Feb-17-26 08:00AM	Clinical Utility of bioAffinity Technologies CyPath Lung Test Demonstrated in Real-World Case Study (Business Wire)
Feb-09-26 08:00AM	bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board (Business Wire) +5.73%
Jan-07-26 08:00AM	bioAffinity Technologies Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation (Business Wire)
Dec-03-25 08:00AM	bioAffinity Technologies Noninvasive CyPath Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable (Business Wire) +9.79%
11:33AM	Loading…
Nov-19-25 11:33AM	BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss (Zacks)
Nov-14-25 08:00AM	bioAffinity Technologies Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-28-25 08:00AM	bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases (Business Wire)
Oct-16-25 08:00AM	bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer (Business Wire) +25.83%
Oct-15-25 08:00AM	bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements (Business Wire) -5.90%
Oct-09-25 02:00PM	WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules (PR Newswire)
01:00PM	bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules (Business Wire)
Oct-08-25 04:15PM	WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules (PR Newswire) +24.49%
03:45PM	bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules (Business Wire)
Oct-07-25 08:00AM	bioAffinity Technologies Reports Record Growth in CyPath Lung Test Volume for Third Quarter 2025 (Business Wire)
Sep-30-25 12:44PM	WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m (PR Newswire) -8.92%
12:15PM	bioAffinity Technologies Announces Closing of $4.8 Million Public Offering (Business Wire)
Sep-29-25 05:59PM	WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m (PR Newswire) -38.56%
03:51PM	bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering (Business Wire)
Sep-26-25 08:00AM	bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath Lung (Business Wire) +55.13%
08:15AM	Loading…
Sep-17-25 08:15AM	bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025 (Business Wire) -30.04%
Sep-09-25 08:00AM	Case Study: CyPath Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules (Business Wire)
Sep-03-25 08:00AM	U.S. Medicine Magazine Spotlights CyPath Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA (Business Wire)
Aug-21-25 02:58PM	BIAF Stock Down Following Q2 Earnings Despite CyPath Lung Growth (Zacks)
Aug-18-25 08:00AM	bioAffinity Technologies Appoints New Members to Board of Directors (Business Wire) +5.11%
Aug-14-25 04:20PM	WallachBeth Capital Announces Closing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds (PR Newswire) -8.86% -8.66%
04:15PM	bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds (Business Wire)
08:00AM	bioAffinity Technologies Reports Second Quarter 2025 Results (Business Wire)
Aug-13-25 10:15AM	WallachBeth Capital Announces Pricing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds (PR Newswire)
09:25AM	bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds (Business Wire)
08:00AM	bioAffinity Technologies Reports Accelerating Growth in CyPath Lung Test Sales (Business Wire)
Jul-29-25 08:00AM	Case Study: CyPath Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results (Business Wire)
Jul-23-25 08:00AM	Case Study: CyPath Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools (Business Wire)
Jul-22-25 09:00AM	Canada Awards New Patent to bioAffinity Technologies for CyPath Lung, Companys Noninvasive Lung Cancer Diagnostic (Business Wire) -6.03%
Jul-15-25 09:00AM	bioAffinity Technologies Announces Notification of China Patent Award for Companys Noninvasive Lung Cancer Diagnostic (Business Wire)
Jul-09-25 09:00AM	Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging (Business Wire)
Jul-01-25 09:33AM	The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies (Zacks) -8.25%
Jun-30-25 04:41PM	Top Research Reports for Meta Platforms, ServiceNow & Booking (Zacks)
Jun-26-25 09:00AM	bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference (Business Wire) +46.90%
Jun-24-25 09:00AM	bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy (Business Wire) +7.73%
Jun-11-25 09:00AM	bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas Leadership Board (Business Wire)
Jun-03-25 09:00AM	bioAffinity Technologies Works With Cardinal Health OptiFreight® Logistics to Help Meet Demand for CyPath® Lung (Business Wire) +7.58%
May-29-25 02:34PM	BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors (Insider Monkey) -15.83%
May-28-25 09:00AM	bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics (Business Wire) +46.84%
May-20-25 12:15PM	BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline (Zacks) +29.79%
09:00AM	bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer (Business Wire)
May-15-25 08:30AM	bioAffinity Technologies Reports First Quarter 2025 Results (Business Wire) -8.62%
May-08-25 09:00AM	Independent White Paper Highlights Real-World Impact of bioAffinity Technologies CyPath® Lung in Diagnosing Early-Stage Lung Cancer (Business Wire) -5.31%
May-07-25 01:15PM	WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering (PR Newswire)
01:00PM	bioAffinity Technologies Announces Closing of $3.25 Million Offering (Business Wire)
10:40AM	BioAffinity Technologies announces pricing of $3.25M offering (TipRanks)
May-06-25 10:30AM	WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering (PR Newswire) -44.50%
09:25AM	bioAffinity Technologies Announces Pricing of $3.25 Million Offering (Business Wire)
09:05AM	The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies (Zacks)
May-05-25 04:23PM	Top Stock Reports for Alphabet, Berkshire Hathaway & Visa (Zacks) -15.27%
Apr-17-25 09:15AM	bioAffinity Technologies Increases Efficiency of CyPath Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost (Business Wire) +9.67%
Apr-07-25 12:16PM	BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues (Zacks)
Mar-31-25 09:28AM	bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 (Business Wire)
Mar-26-25 09:00AM	Case Study: bioAffinity Technologies CyPath Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer (Business Wire)
Mar-19-25 09:00AM	Case Study: bioAffinity Technologies Positive CyPath Lung Result Leads to Detecting Breast Cancer Recurrence (Business Wire)
Mar-13-25 09:00AM	Physicians Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer (Business Wire) -13.73%
Mar-06-25 08:00AM	bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath Lung Sales Growth (Business Wire)
Feb-26-25 12:10PM	WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million (PR Newswire) -11.08%
11:30AM	bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million (Business Wire)
Feb-25-25 11:05AM	WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million (PR Newswire) -16.67%
09:58AM	bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million (Business Wire)
Jan-22-25 08:00AM	bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic (Business Wire)
Jan-13-25 08:00AM	bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath Lung (Business Wire) -6.83%
Jan-10-25 09:00AM	Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) -12.06%
Dec-21-24 06:33AM	bioAffinity Technologies Boosts Sales with CyPath Lung (TipRanks)
Dec-17-24 08:00AM	Join bioAffinity Technologies Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19 (Business Wire) +15.84%
Dec-12-24 08:00AM	bioAffinity Technologies Set for Continued Expansion in 2025 (Business Wire)
Dec-05-24 08:00AM	Veterans Research Foundation Spotlights CyPath Lungs Addition to the Federal Supply Schedule (Business Wire)
Nov-14-24 08:00AM	bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 (Business Wire)
Nov-04-24 08:00AM	bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development (Business Wire)
Oct-30-24 08:00AM	bioAffinity Technologies Announces Award of Japanese Patent for CyPath Lung (Business Wire) +5.38%
Oct-21-24 11:39AM	WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement (PR Newswire)
10:45AM	bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement (Business Wire)
Oct-18-24 02:57PM	WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement (PR Newswire) -33.80%
12:45PM	bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement (Business Wire)
Oct-16-24 08:00AM	bioAffinitys CyPath Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines (Business Wire) +10.10%
Oct-10-24 08:00AM	bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer (Business Wire)
Oct-09-24 08:00AM	bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath Lung Test (Business Wire) +13.71%
Sep-18-24 08:00AM	Peer-Reviewed Study: bioAffinity Technologies CyPath Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis (Business Wire)
Aug-23-24 05:15PM	bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO (Business Wire)
Aug-14-24 09:25AM	bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath Lung Sales (Business Wire)
Aug-05-24 02:00PM	WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million (PR Newswire)
01:17PM	bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million (Business Wire)
Aug-02-24 10:00AM	WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million (PR Newswire) -27.31%
09:25AM	bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million (Business Wire)

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIAF

BioAffinity Technologies Inc

Upgrade your Finviz experience